Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone

European Archives of Psychiatry and Clinical Neuroscience

Volumn 261, Issue 4, 2011, Pages 231-239

  De Hert, Marc ^a   Mittoux, Aurélia ^b   He, Yuan ^b   Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b H LUNDBECK A S   (Denmark)

Author keywords

Metabolic syndrome; Risperidone; Schizophrenia; Sertindole; Side effects

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPENTIXOL; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIACYLGLYCEROL; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INDOLES; LIPIDS; MALE; METABOLIC DISEASES; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 79960214714     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-010-0142-x     Document Type: Article

References (56)

1. KG Alberti P Zimmet J Shaw 2006 Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation Diabetic Med 23 469 480 16681555 10.1111/j.1464-5491.2006.01858.x 1:STN:280:DC%2BD283lslGgsQ%3D%3D
2. American Diabetes Association 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 27 596 601 10.2337/diacare.27.2.596 (Pubitemid 38180442)
3. AH Barnett P Mackin I Chaudhry A Farooqi R Gadsby A Heald J Hill H Millar R Peveler A Rees V Singh D Taylor J Vora PB Jones 2007 Minimising metabolic and cardiovascular risk in schizophrenia J Psychopharmacol 21 4 357 373 17656425 10.1177/0269881107075509 1:CAS:528:DC%2BD2sXptFGqu74%3D (Pubitemid 47077296)
4. PF Buckley DD Mille B Singer 2005 Clinicians' recognition of the metabolic adverse effects of antipsychotic medications Schizophr Res 79 281 288 15964743 10.1016/j.schres.2005.04.010 (Pubitemid 41457268)
5. Byrne CD, Wild SH (2005) The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Byrne CD, Wild SH (eds) The metabolic syndrome. Wiley, West Sussex, pp 1-42
6. DE Casey DW Haupt JW Newcomer DC Henderson MJ Sernyak M Davidson JP Lindenmayer SV Manoukian MA Banerji HE Lebovitz CH Hennekens 2004 Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia J Clin Psychiatry 65 Suppl 7 4 18 15151456
7. CU Correll 2007 Balancing efficacy and safety in the treatment with antipsychotics CNS Spectr 12 Suppl 17 2 20
8. GL Daumit DC Goff JM Meyer VG Davis HA Nasrallah JP McEvoy R Rosenheck SM Davis JK Hsiao TS Stroup JA Lieberman 2008 Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study Schizophr Res 105 1-3 175 187 18775645 10.1016/j.schres.2008.07.006
9. M De Hert D Van Eyck A De Nayer 2006 Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring Int Clin Psychopharmacol 21 Suppl 2 11 15 10.1097/01.yic.0000201496.23259.85
10. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2:14 (online)
11. M De Hert V Schreurs K Sweers D Van Eyck L Hanssens S Šinko R van Winkel M Wampers J Peuskens 2008 Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review Schizophr Res 101 1-3 295 303 18299188 10.1016/j.schres.2008.01.028
12. M De Hert JM Dekker D Wood KG Kahl HJ Möller 2009 Cardiovascular disease and diabetes in people with severe mental illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) Eur Psychiatry 24 6 412 424 19682863 10.1016/j.eurpsy.2009.01. 005
13. M De Hert V Schreurs D Vancampfort R van Winkel 2009 Metabolic syndrome in people with schizophrenia: a review World Psychiatry 8 1 15 22
14. M De Hert CU Correll D Cohen 2010 Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study Schizophr Res 117 1 68 74 20060684 10.1016/j.schres.2009.12.029
15. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
16. WW Fleischhacker M Cetkovich-Bakmas M De Hert CH Hennekens M Lambert S Leucht M Maj RS McIntyre D Naber JW Newcomer M Olfson U Osby N Sartorius JA Lieberman 2008 Cormorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges J Clin Psychiatry 69 514 519 18370570 10.4088/JCP.v69n0401 (Pubitemid 351792324)
17. E Gale 2005 The myth of the metabolic syndrome Diabetologica 48 679 683
18. DC Goff LM Sullivan JP McEvoy JM Meyer HA Nasrallah GL Daumit S Lamberti RB D'Agostino TS Stroup S Davis JA Lieberman 2005 A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Schizophr Res 80 1 45 53 16198088 10.1016/j.schres.2005.08.010 (Pubitemid 41587462)
19. SM Grundy 2005 The changing face of cardiovascular risk JACC 46 173 176 15992653
20. SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin DJ Gordon RM Krauss PJ Savage SC Smith JA Spertus F Costa 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2735 2752 16157765 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
21. A Hale JM Azorin S Kasper W Maier E Syvalahti M Van Der Burght M Sloth-Nielsen A Wehnert 2000 Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a phase III trial Int J Psychiatry Clin Pract 4 47 54 10.1080/13651500052048758 1:CAS:528:DC%2BD3cXivVCgurw%3D (Pubitemid 30198336)
22. DW Haupt LC Rosenblatt E Kim RA Baker R Whitehead JW Newcomer 2009 Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents Am J Psychiatry 166 3 345 353 19147694 10.1176/appi.ajp.2008.08030383
23. CH Hennekens AR Hennekens D Hollar DE Casey 2005 Schizophrenia and increased risks of cardiovascular disease Am Heart J 150 6 1115 1121 16338246 10.1016/j.ahj.2005.02.007 (Pubitemid 41773510)
24. B Isomaa P Almgren T Tuomi B Forsen K Lahti M Nissen MR Taskinen L Groop 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 4 683 689 11315831 10.2337/diacare.24.4.683 1:STN:280:DC%2BD3MvjsVOqsw%3D%3D (Pubitemid 32893993)
25. S Kasper 2002 Serindole: safety and tolerability profile Int J Psych Clin Pract 6 Suppl 1 S27 S32 10.1080/13651500215967 1:CAS:528:DC%2BD3sXhvV2itb0%3D
26. S Kasper HJ Möller A Hale 2010 The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment Eur Arch Psychiatry Clin Neurosci 260 1 59 68 19455275 10.1007/s00406-009-0018-0
27. TM Laursen T Munk-Olsen E Agerbo C Gasse PB Mortensen 2009 Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder Arch Gen Psychiatry 66 7 713 720 19581562 10.1001/archgenpsychiatry.2009.61
28. S Leucht T Burkard J Henderson M Maj N Sartorius 2007 Physical illness and schizophrenia: a review of the literature Acta Psychiatr Scand 116 317 333 17919153 10.1111/j.1600-0447.2007.01095.x 1:STN:280:DC%2BD2srpvFWrsQ%3D%3D (Pubitemid 47537428)
29. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 9657 31 41 19058842 10.1016/S0140-6736(08)61764-X 1:CAS:528:DC%2BD1MXht1Wqsw%3D%3D
30. S Leucht K Komossa C Rummel-Kluge C Corves H Hunger F Schmid C Asenjo Lobos S Schwarz JM Davis 2009 A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 166 2 152 163 19015230 10.1176/appi.ajp.2008.08030368
31. E Lindstrom S Levander 2006 Sertindole: efficacy and safety in schizophrenia Expert Opin Pharmacother 7 1825 1834 16925508 10.1517/14656566.7. 13.1825
32. SR Marder SM Essock AL Miller RW Buchanan DE Casey JM Davis JM Kane JA Lieberman NR Schooler N Covell S Stroup EM Weissman DA Wirshing CS Hall L Pogach X Pi-Sunyer JT Bigger A Friedman D Kleinberg SJ Yevich B Davis S Shon 2004 Physical health monitoring of patients with schizophrenia Am J Psychiatry 161 8 1334 1349 15285957 10.1176/appi.ajp.161.8.1334 (Pubitemid 38989085)
33. JM Meyer VG Davis DC Goff JP McEvoy HA Nasrallah SM Davis RA Rosenheck GL Daumit J Hsiao MS Swartz TS Stroup JA Lieberman 2008 Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1 Schizophr Res 101 1-3 273 286 18258416 10.1016/j.schres.2007.12.487
34. Meyer JM, Nasrallah HA (2003) Medical illness and schizophrenia. American Psychiatric Publishing, Washington, DC
35. JM Meyer SM Stahl 2009 The metabolic syndrome and schizophrenia Acta Psychiatr Scand 119 1 4 14 19133915 10.1111/j.1600-0447.2008.01317.x 1:STN:280:DC%2BD1M%2FmtlKqug%3D%3D
36. HA Nasrallah JM Meyer DC Goff JP McEvoy SM Davis TS Stroup J Liberman 2006 Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline Schizophr Res 86 1-3 15 22 16884895 10.1016/j.schres.2006.06.026 (Pubitemid 44234064)
37. JW Newcomer HA Nasrallah AD Loebel 2004 The atypical antipsychotic therapy and metabolic issues national survey J Clin Psychopharmacol 24 1 6 10.1097/01.jcp.0000142281.85207.d5 (Pubitemid 39265948)
38. J Newcomer 2007 Metabolic syndrome and mental illness Am J Manag Care 13 170 177
39. JW Newcomer 2005 Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl 1 1 93 15998156 1:CAS:528:DC%2BD2MXltFCqu74%3D (Pubitemid 40677047)
40. U Osby N Correia L Brandt A Ekbom P Sparen 2000 Mortality and causes of death in schizophrenia in Stockholm County, Sweden Schizophr Res 45 1-2 21 28 10978869 10.1016/S0920-9964(99)00191-7 1:STN:280:DC%2BD3cvpt1Wquw%3D%3D
41. U Osby N Correia L Brandt A Ekbom P Sparen 2000 Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study BMJ 321 7259 483 484 10948028 10.1136/bmj.321.7259.483 1:STN:280:DC%2BD3cvlsFWjtA%3D%3D (Pubitemid 30623604)
42. J Peuskens N Moore JM Azorin M Toumi J Cochran 2007 The European sertindole safety and exposure survey: a follow-up study of 8600 patients Pharmacoepidemiol Drug Saf 16 7 804 811 17551996 10.1002/pds.1425 (Pubitemid 47180370)
43. J Peuskens P Tanghøj A Mittoux Sertindole Cohort 2008 The Sertindole Cohort Prospective (SCoP) study: rationale, design and methodology Pharmacoepidemiol Drug Saf 17 5 425 433 18384186 10.1002/pds.1594 (Pubitemid 351722028)
44. S Saha D Chant J Mcgrath 2007 A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64 1123 1131 17909124 10.1001/archpsyc.64.10.1123 (Pubitemid 47529346)
45. A Scheen M De Hert 2007 Abnormal glucose metabolism in patients treated with antipsychotics Diabetes Metabol 33 169 175 10.1016/j.diabet.2007.01.003 1:CAS:528:DC%2BD2sXptFGntbc%3D (Pubitemid 46876639)
46. A Scheen R van Winkel M De Hert 2008 Traitement neuroleptique et troubles metabolic Med Mal Metabol 2 6 593 599
47. SG Schorr CJ Slooff R Bruggeman K Taxis 2008 Incidence of metabolic syndrome and its reversibility in a cohort of schizophrenic patients followed for one year Schizophr Res 102 Suppl 241
48. V Simon R van Winkel M De Hert 2009 Are weight gain and metabolic side-effects of atypical antipsychotics dose-dependent? A literature review J Clin Psychiatry 70 7 1041 1050 19653979 10.4088/JCP.08r04392 1:CAS:528:DC%2BD1MXhsFentbnK
49. M Smith D Hokins R Peveler R Holt M Woodward K Ismail 2008 First versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis Br J Psychiatry 192 6 406 411 18515889 10.1192/bjp.bp.107.037184 1:STN:280:DC%2BD1czltFensA%3D%3D (Pubitemid 351809892)
50. J Tiihonen J Lönnqvist K Wahlbeck T Klaukka L Niskanen A Tanskanen J Haukka 2009 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet 374 9690 620 627 19595447 10.1016/S0140-6736(09)60742-X
51. A Tschoner J Engl M Laimer S Kaser M Rettenbacher W Fleischhacker J Patsch C Ebenbichler 2007 Metabolic side effects of antipsychotic medication Int J Clin Pract 61 8 1356 1370 17627711 10.1111/j.1742-1241.2007.01416.x 1:CAS:528:DC%2BD2sXpvFSnu7k%3D (Pubitemid 47052363)
52. Thomas SHL, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, Le Jeunne C, Naber D, Priori S, Sturkenboom M, Thibaut F, Peuskens J, Mittoux A, Tanghøj P, Toumi M, Moore ND, Mann RD (2010) Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 1-11. doi: 10.1111/j.1600-0447. 2010.01563.x
53. R van Winkel M De Hert D Van Eyck L Hanssens M Wampers A Scheen J Peuskens 2006 Screening for diabetes and other metabolic abnormalities in patients with schizophrenia: evaluation of incidence and screening methods J Clin Psychiatry 67 10 1493 1500 17107239 10.4088/JCP.v67n1002 (Pubitemid 44787430)
54. S Weinmann J Read V Aderhold 2009 Influence of antipsychotics on mortality in schizophrenia: systematic review Schizophr Res 113 1 1 11 19524406 10.1016/j.schres.2009.05.018
55. S Yusuf S Hawken S Ounpuu T Dans A Avezum F Lanas M McQueen A Budaj P Pais J Varigos L Lisheng INTERHEART Study Investigators 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 9438 937 952 15364185 10.1016/S0140-6736(04)17018-9 (Pubitemid 39208455)
56. DL Zimbroff JM Kane CA Tamminga DG Daniel RJ Mack PJ Wozniak TB Sebree BA Wallin KB Kaskin 1997 Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group Am J Psychiatry 154 782 791 9167505 1:STN:280:DyaK2szhtVegug%3D%3D (Pubitemid 27230100)